Neuland Laboratories Receives SEBI Warning for Insider Trading Violation

On 17 June 2025, Neuland Laboratories Limited made a regulatory disclosure in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed the stock exchanges about the receipt of an administrative warning letter from SEBI concerning a violation under the Prohibition of Insider Trading Regulations. While the incident involved a designated person within the company, the management confirmed that it does not materially affect the company's financial or operational standing.

SEBI Observes Violation of Insider Trading Regulations

According to the official disclosure, the Compliance Officer of Neuland Laboratories received an administrative warning letter dated 13 June 2025 from the Deputy General Manager at SEBI. The letter relates to a violation of the SEBI (Prohibition of Insider Trading) Regulations, 2015, particularly concerning the pre-clearance requirements by a designated person of the company. The warning serves as a regulatory communication, without imposing any financial penalty or operational restrictions on the company.

Neuland Laboratories Q4 FY25 Reults

Neuland Laboratories posted weak financial results for the quarter ended March 2025. Net profit for the period dropped by 59% year-on-year to ₹27.8 crore. Revenue fell 15% to ₹328 crore from ₹385 crore in the corresponding quarter of the previous year. EBITDA also declined by 52% year-on-year to ₹51.1 crore, while EBITDA margins narrowed sharply from 27.8% to 16%. These figures reflect operational challenges faced during the quarter.

Read More: Neuland Laboratories Q4 FY2025 Results!

Neuland Laboratories Share Price Performance 

As of June 18, 2025, at 10:30 AM, Neuland Laboratories share price is trading at 12,476.00 per share, reflecting a decline of 0.45% from the previous closing price. Over the past month, the stock has declined by 11.21%

Conclusion

While the receipt of an administrative warning reflects SEBI’s scrutiny in enforcing insider trading norms, Neuland Laboratories has maintained transparency by promptly disclosing the matter. The company reiterated that the issue does not affect its core operations or financial performance.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.